Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease.

Paula McClean, Victor Gault, Patrick Harriott, Christian Holscher

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1). The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus. At a dose of 15nmol in 5microl i.c.v., Liraglutide (P
LanguageEnglish
Pages158-162
JournalEuropean Journal of Pharmacology
Volume630
Issue number1-3
Early online date24 Dec 2009
DOIs
Publication statusPublished - 25 Mar 2010

Fingerprint

Neuronal Plasticity
Glucagon-Like Peptide 1
Alzheimer Disease
Insulin
Brain
Incretins
Type 2 Diabetes Mellitus
Hippocampus
Hormones
Enzymes
Liraglutide

Cite this

@article{fe6675198c62468d980523c341c3815b,
title = "Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease.",
abstract = "Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1). The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus. At a dose of 15nmol in 5microl i.c.v., Liraglutide (P",
author = "Paula McClean and Victor Gault and Patrick Harriott and Christian Holscher",
year = "2010",
month = "3",
day = "25",
doi = "10.1016/j.ejphar.2009.12.023",
language = "English",
volume = "630",
pages = "158--162",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. / McClean, Paula; Gault, Victor; Harriott, Patrick; Holscher, Christian.

In: European Journal of Pharmacology, Vol. 630, No. 1-3, 25.03.2010, p. 158-162.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease.

AU - McClean, Paula

AU - Gault, Victor

AU - Harriott, Patrick

AU - Holscher, Christian

PY - 2010/3/25

Y1 - 2010/3/25

N2 - Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1). The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus. At a dose of 15nmol in 5microl i.c.v., Liraglutide (P

AB - Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1). The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus. At a dose of 15nmol in 5microl i.c.v., Liraglutide (P

U2 - 10.1016/j.ejphar.2009.12.023

DO - 10.1016/j.ejphar.2009.12.023

M3 - Article

VL - 630

SP - 158

EP - 162

JO - European Journal of Pharmacology

T2 - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -